Latest news with #GudrunFeuchtner
Yahoo
02-04-2025
- Health
- Yahoo
Cleerly CONFIRM2 study finds women with CAD at higher risk of MACE
Cleerly has announced interim results from a trial, described as the largest-ever cardiovascular phenotype outcomes study, finding that women living with chronic coronary artery disease (CAD) are at higher risk of major adverse coronary events (MACE) than men. The Cleerly CONFIRM2 trial was a retrospective and prospective, open-label trial that examined 3,551 patients to determine if AI-based Quantitative Computed Tomography (AI-QCT) could be used to predict mortality and MACE. By design, 49.5% of the trial population comprised of women. Results found that while the overall burden for CAD in the population studied fell mostly on men, women were at higher risk of developing MACE than men due to higher rates of plaque volume, calcified plaque, non-calcified plaque, and percentage atheroma volumes detected through AI-QCT. Lead researcher for the Cleerly study, Gudrun Feuchtner, spoke with Clinical Trials Arena shortly after unveiling the results at the 2025 American College of Cardiology's Annual Scientific Expo, arguing that the adoption of AI-QCT over traditional QCT could improve clinical outcomes for women. Feuchtner said: 'We had one main analysis, and we focused on the differences between men and women because heart disease is under-diagnosed in women and outcomes for women are worse. 'Currently in cardiology, we [have tools to measure] risk factors, but the performance of these [measurements] is very poor. AI analysis can more precisely stratify the different layers of atherosclerosis, so not only can we quantify calcium, but we can also quantify other components like calcified plaque, non-calcified plaque or lipid necrotic-rich core plaque, which puts an individual at even higher risk. In the trial, we found that these features enhance risk prediction in women more than men.' The Cleerly study, titled: 'AI-Quantitative CT Coronary Plaque Features Associate with a Higher Relative Risk in Women: CONFIRM2-Registry' joins research published in 2024, namely the CREDENCE (NCT02173275) and PACIFIC-1 (NCT01521468) studies, both of which also found Cleerly's AI Ischemia QCT system able to predict MACE in CAD patients. Elsewhere in the field of cardiac devices, Johnson & Johnson MedTech's Shockwave Medical has launched its Javelin Peripheral IVL Catheter in the US for peripheral artery disease (PAD). "Cleerly CONFIRM2 study finds women with CAD at higher risk of MACE" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
27-03-2025
- Health
- Yahoo
Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC.25
Cleerly to Present Late-Breaking Findings and Participate in Key ACC.25 Sessions DENVER, March 27, 2025--(BUSINESS WIRE)--Cleerly, the leader in cardiovascular AI imaging, announces its participation in the American College of Cardiology Annual Scientific Session + Expo (ACC.25) from March 29-31, 2025, at the McCormick Place Convention Center in Chicago, Illinois. Cleerly will share its late-breaking findings on Artificial Intelligence-based Quantitative Computed Tomography's (AI-QCT's) role in identifying risks of future major adverse cardiovascular events (MACE) in women. Onsite, Cleerly will demonstrate the company's AI-enabled coronary computed tomography angiography (CCTA) solution to help guide personalized prognosis, diagnosis, and treatment of coronary artery disease (CAD). Late-Breaking Clinical Trial Presentation In the session "Clinical and Investigative Horizons" on March 31st at 9:00 AM, Dr. Gudrun Feuchtner will present late-breaking clinical research titled "Artificial Intelligence-based Quantitative Computed Tomography (AI-QCT) Coronary Plaque Features Predict Risk More Pronounced in Females: The International Multicentric Registry CONFIRM2," on behalf of the CONFIRM2 investigators. This groundbreaking research will shine a light on the potential role of Cleerly's AI-QCT for measuring disease in women, in whom coronary artery disease is often underdiagnosed and undertreated. CONFIRM2 is one of the few studies in which about 50% of the participants are female. With a diverse trial population of 3,500 participants from sites across 11 countries, this study highlights the generalized applicability of the results in addressing cardiovascular health disparities. Sessions and Abstracts Cleerly's founder and CEO, Dr. James Min, will be featured on the Health Equity Panel on March 30th from 2:30 - 3:30 PM. This session, titled "Championing Communities of Health: A Cross-Industry Panel Discussion on Community Education, Cardiovascular Disease Prevention, and Screening Programs," will address critical issues surrounding health equity and the importance of community engagement in cardiovascular health. Cleerly will also participate in a Lounge & Learn Session titled "Increasing Female Physician Leadership in Clinical Trials" on March 30th from 1:00 - 1:30 PM in the Education Zone, Theater 1 of the Lounge and Learn Pavilion. Additionally, Cleerly will present six additional abstracts throughout the conference, showcasing advancements in heart health technology and research. Visit Cleerly at Booth #16033 Stop by and learn more about Cleerly at booth #16033, where a coffee bar with barista service will be available for all visitors. The Cleerly team will be available to demonstrate the technology, including its COMPARE feature, which enables clinicians to track the progression of plaque over time. Attendees can also stop by Cleerly's "Meet Cleerly Leadership" event on Sunday, March 30th from 12:30 to 1:30 PM, for an opportunity to talk with Cleerly leadership and enjoy a complimentary lunch-style buffet. To see a full schedule of Cleerly presentations or schedule a meeting with Cleerly leadership, please visit this link. About Cleerly Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly's approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: View source version on Contacts Cleerly Media Contact Christy Sievertpress@
